Riskpilot← Back to searchSign inGet full accessLovisa Läkar AB
ABActiveOrg 5590675582Torggatan 1 BvMedical specialists activities · NACE 8622Est. 20165 employees
Revenue 2025
SEK 9,5M
+7% vs 2024
EBITDA margin
18.1%
+30% vs 2024
Equity ratio
52.4%
Financial strength
Net profit 2025
SEK 1,3M
+33% vs 2024
| Revenue | SEK 9,5M | +7% |
| EBITDA | SEK 1,7M | +30% |
| Net profit | SEK 1,3M | +33% |
| Total assets | SEK 2,6M | +30% |
| Equity | SEK 1,4M | +27% |
| Employees | 5 | — |
Legal name
Lovisa Läkar AB
Org number
5590675582
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
23 juni 2016
Share capital
SEK 50 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget skall bedriva läkarverksamhet inom ortopedi, kvinnosjukdomar, förlossningar, forskning och utbildning samt därmed förenlig verksamhet. Bolaget skall också erbjuda tjänster inom skönhetsvård. Vidare skall bolaget äga och förvalta värdepapper samt därmed förenlig verksamhet.
Address
Torggatan 1 Bv
Email
yana.leonova@icloud.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 433 | 7 698 | 9 053 | 8 944 | 9 546 |
| Staff expenses | — | — | −4 636 | −4 236 | −4 214 |
| EBITDA | 611 | −83 | 884 | 1 330 | 1 727 |
| Depreciation & amort. | −308 | −91 | −44 | −67 | −65 |
| EBIT | 303 | −174 | 840 | 1 263 | 1 662 |
| Net financials | −12 | −13 | −13 | −12 | −12 |
| Profit before tax | 351 | −187 | 827 | 1 252 | 1 650 |
| Tax | −86 | −0 | −158 | −275 | −354 |
| Net profit | 265 | −187 | 670 | 976 | 1 295 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 252 | 915 | 1 715 | 2 015 | 2 626 |
| Equity | 331 | −116 | 554 | 1 080 | 1 376 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 921 | 1 031 | 1 161 | 935 | 1 251 |
| Total debt | 921 | 1 031 | 1 161 | 935 | 1 251 |
EBITDA margin
18.1%
This company
15.8%
Market median
+15% vs market
20212025
Equity ratio
52.4%
This company
38.2%
Market median
+37% vs market
20212025
Return on equity
94.2%
This company
18.4%
Market median
+412% vs market
20212025
Net profit margin
13.6%
This company
8.1%
Market median
+68% vs market
20212025
Asset turnover
3.63×
This company
1.12×
Market median
+224% vs market
20212025
Debt / equity
0.91×
This company
0.62×
Market median
+47% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AL Chief Executive Officer | Chief Executive Officer | 2022 |
NO Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
AK | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lovisa Läkar AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andrey Leonov | Chief Executive Officer | 0 companies |
| Anders Kristian Lyngenberg | Audit | 0 companies |
| Nils Olov Linus Eriksson | Chief Auditor | 0 companies |
| Yana Leonova | Board of Directors | 0 companies |